Literature DB >> 666946

Plasma concentrations of isosorbide dinitrate and its metabolites after chronic high oral dosage in man.

S J Shane, J J Iazzetta, A W Chisholm, J F Berka, D Leung.   

Abstract

1 We have previously reported that vasodilator headache due to isosorbide dinitrate (ISDN) can be circumvented by using small 'priming' doses for an induction period of 1-2 weeks, after which it is possible to increase to dose rapidly to 360-720 mg, daily without recurrence of headache and without toxicity. The present study corroborates this earlier finding. 2. Chronic oral administration of doses of ISDN of this order of magnitude results in prolonged high plasma concentrations of the parent compound, as well as higher levels of the metabolites 2-ISMN and 5-ISMN. 3. It is our thesis that chronic high oral dosage of ISDN saturates the intrahepatic biotransformation process, and allows high concentrations of ISDN and its metabolites to enter the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 666946      PMCID: PMC1429383          DOI: 10.1111/j.1365-2125.1978.tb01679.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  GLC determination of nitroglycerin and isosorbide dinitrate in human plasma.

Authors:  M T Rosseel; M G Bogaert
Journal:  J Pharm Sci       Date:  1973-05       Impact factor: 3.534

2.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

Review 3.  Organic nitrate metabolism.

Authors:  P Needleman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1976       Impact factor: 13.820

4.  Clearance and metabolism of organic nitrates.

Authors:  E M Johnson; A B Harkey; D J Blehm; P Needleman
Journal:  J Pharmacol Exp Ther       Date:  1972-07       Impact factor: 4.030

5.  Systemic and coronary vascular effects of the 2- and the 5-mononitrate esters of isosorbide.

Authors:  R L Wendt
Journal:  J Pharmacol Exp Ther       Date:  1972-03       Impact factor: 4.030

6.  Organic nitrates: relationship between biotransformation and rational angina pectoris therapy.

Authors:  P Needleman; S Lang; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

7.  Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects.

Authors:  L F Chasseaud; W H Down; R K Grundy
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

8.  Comparative vasodilator effects of nitroglycerin, pentaerythritol trinitrate and biometabolites, and other organic nitrates.

Authors:  J C Parker; F J Di Carlo; I W Davidson
Journal:  Eur J Pharmacol       Date:  1975-03       Impact factor: 4.432

9.  Vascular effects of the dinitrate and moninitrate esters of isosorbide, isomannide and isoidide.

Authors:  M G Bogaert; M T Rosseel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

10.  The metabolic fate of nitroglycerin (trinitrin) in relation to its vascular effects.

Authors:  M G Bogaert; M T Rosseel; A F De Schaepdryver
Journal:  Eur J Pharmacol       Date:  1970-10       Impact factor: 4.432

  10 in total
  8 in total

1.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

2.  Kinetics of isosorbide dinitrate and relationships to pharmacological effects.

Authors:  H L Fung; E F McNiff; D Ruggirello; A Darke; U Thadani; J O Parker
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

3.  Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.

Authors:  Y Santoni; A Iliadis; J P Cano; R Luccioni; Y Frances
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

4.  High-dosage isosorbide dinitrate therapy for angina.

Authors:  G Tremblay; P Biron; F Désourdy
Journal:  Can Med Assoc J       Date:  1983-03-15       Impact factor: 8.262

Review 5.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

6.  Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Authors:  M G Bogaert; M T Rosseel; J Boelaert; R Daneels
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Effects and pharmacokinetics of isosorbide dinitrate in normal man.

Authors:  S Spörl-Radun; G Betzien; B Kaufmann; V Liede; U Abshagen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

8.  Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.

Authors:  R E Finch; M R Bending; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.